Vertex Pharmaceuticals
Vertex Pharmaceuticals (VRTX) reported consolidated financial 2024 results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance.

Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex Pharmaceuticals said, “Vertex delivered a strong start to 2024 with 13 percent product revenue growth and outstanding execution across the business. This quarter, we continued to expand our leadership . . .